A small molecule agonist THIQ as a novel pharmacoperone for intracellularly retained melanocortin-4 receptor mutants

International Journal of Biological Sciences

Volumn 10, Issue 8, 2014, Pages 817-824

  Huang, Hui ^a   Tao, Ya Xiong ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

G protein coupled receptor; Melanocortin 4 receptor; Obesity; Pharmacological chaperone pharmacoperone; THIQ

Indexed keywords

MELANOCORTIN 4 RECEPTOR; N-(1,2,3,4-TETRAHYDROISOQUINOLINIUM-3-YLCARBONYL)-1-(4-CHLOROBENZYL)-2-(4-CYCLOHEXYL-4-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PIPERIDIN-1-YL)-2-OXOETHYLAMINE; TETRAHYDROISOQUINOLINE DERIVATIVE; TRIAZOLE DERIVATIVE;

AGONISTS; CONFOCAL MICROSCOPY; FLOW CYTOMETRY; GENETICS; HEK293 CELL LINE; HUMAN;

FLOW CYTOMETRY; HEK293 CELLS; HUMANS; MICROSCOPY, CONFOCAL; RECEPTOR, MELANOCORTIN, TYPE 4; TETRAHYDROISOQUINOLINES; TRIAZOLES;

EID: 84906736273     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.9625     Document Type: Article

References (36)

1. Gantz I, Konda Y, Tashiro T, Shimoto Y, Miwa H, Munzert G, et al. Molecular cloning of a novel melanocortin receptor. J Biol Chem. 1993; 268: 8246-50.
2. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell. 1997; 88: 131-41.
3. Tao YX. Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity. Mol Cell Endocrinol. 2005; 239: 1-14.
4. Tao YX. Mutations in melanocortin-4 receptor and human obesity. Prog Mol Biol Transl Sci. 2009; 88: 173-204.
5. Hinney A, Volckmar AL, Knoll N. Melanocortin-4 receptor in energy homeostasis and obesity pathogenesis. Prog Mol Biol Transl Sci. 2013; 114: 147-91.
6. Meimaridou E, Gooljar SB, Ramnarace N, Anthonypillai L, Clark AJ, Chapple JP. The cytosolic chaperone Hsc70 promotes traffic to the cell surface of intracellular retained melanocortin-4 receptor mutants. Mol Endocrinol. 2011; 25: 1650-60.
7. Granell S, Mohammad S, Ramanagoudr-Bhojappa R, Baldini G. Obesity-linked variants of melanocortin-4 receptor are misfolded in the endoplasmic reticulum and can be rescued to the cell surface by a chemical chaperone. Mol Endocrinol. 2010; 24: 1805-21.
8. Fan ZC, Tao YX. Functional characterization and pharmacological rescue of melanocortin-4 receptor mutations identified from obese patients. J Cell Mol Med. 2009; 13: 3268-82.
9. Rene P, Le Gouill C, Pogozheva ID, Lee G, Mosberg HI, Farooqi IS, et al. Pharmacological chaperones restore function to MC4R mutants responsible for severe early-onset obesity. J Pharmacol Exp Ther. 2010; 335: 520-32.
10. Tao YX. The melanocortin-4 receptor: Physiology, pharmacology, and pathophysiology. Endocr Rev. 2010; 31: 506-43.
11. Ward NA, Hirst S, Williams J, Findlay JB. Pharmacological chaperones increase the cell-surface expression of intracellularly retained mutants of the melanocortin 4 receptor with unique rescuing efficacy profiles. Biochem Soc Trans. 2012; 40: 717-20.
12. Granell S, Molden BM, Baldini G. Exposure of MC4R to agonist in the endoplasmic reticulum stabilizes an active conformation of the receptor that does not desensitize. Proc Natl Acad Sci U S A. 2013; 110: E4733-E42.
13. Conn PM, Ulloa-Aguirre A, Ito J, Janovick JA. G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo. Pharmacol Rev. 2007; 59: 225-50.
14. Conn PM, Ulloa-Aguirre A. Pharmacological chaperones for misfolded gonadotropin-releasing hormone receptors. Adv Pharmacol. 2011; 62: 109-41.
15. Tao YX, Conn PM. Chaperoning G protein-coupled receptors: From cell biology to therapeutics. Endocr Rev. 2014; 35: 602-47.
16. Bernier V, Morello JP, Zarruk A, Debrand N, Salahpour A, Lonergan M, et al. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol. 2006; 17: 232-43.
17. Janovick JA, Stewart MD, Jacob D, Martin LD, Deng JM, Stewart CA, et al. Restoration of testis function in hypogonadotropic hypogonadal mice harboring a misfolded GnRHR mutant by pharmacoperone drug therapy. Proc Natl Acad Sci U S A. 2013; 110: 21030-5.
18. Sebhat IK, Martin WJ, Ye Z, Barakat K, Mosley RT, Johnston DB, et al. Design and pharmacology of N-[(3R)-1, 2, 3, 4-tetrahydroisoquinolinium-3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)-2-[4-cyclohexyl-4-(1H-1, 2, 4-triazol-1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist. J Med Chem. 2002; 45: 4589-93.
19. Tao YX, Huang H, Wang ZQ, Yang F, Williams JN, Nikiforovich GV. Constitutive activity of neural melanocortin receptors. Methods Enzymol. 2010; 484: 267-79.
20. Tao YX, Segaloff DL. Functional characterization of melanocortin-4 receptor mutations associated with childhood obesity. Endocrinology. 2003; 144: 4544-51.
21. Tao YX, Segaloff DL. Functional analyses of melanocortin-4 receptor mutations identified from patients with binge eating disorder and nonobese or obese subjects. J Clin Endocrinol Metab. 2005; 90: 5632-8.
22. Tao YX. Functional characterization of novel melanocortin-3 receptor mutations identified from obese subjects. Biochim Biophys Acta. 2007; 1772: 1167-74.
23. Wang ZQ, Tao YX. Functional studies on twenty novel naturally occurring melanocortin-4 receptor mutations. Biochim Biophys Acta. 2011; 1812: 1190-9.
24. Huang H, Tao YX. Pleiotropic functions of the transmembrane domain 6 of human melanocortin-4 receptor. J Mol Endocrinol. 2012; 49: 237-48.
25. Wang SX, Fan ZC, Tao YX. Functions of acidic transmembrane residues in human melanocortin-3 receptor binding and activation. Biochem Pharmacol. 2008; 76: 520-30.
26. Biebermann H, Krude H, Elsner A, Chubanov V, Gudermann T, Gruters A. Autosomal-dominant mode of inheritance of a melanocortin-4 receptor mutation in a patient with severe early-onset obesity is due to a dominant-negative effect caused by receptor dimerization. Diabetes. 2003; 52: 2984-8.
27. Donohoue PA, Tao YX, Collins M, Yeo GSH, O'Rahilly S, Segaloff DL. Deletion of codons 88-92 of the melanocortin-4 receptor gene: a novel deleterious mutation in an obese female. J Clin Endocrinol Metab. 2003; 88: 5841-5.
28. Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O'Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med. 2003; 348: 1085-95.
29. Gao Z, Lei D, Welch J, Le K, Lin J, Leng S, et al. Agonist-dependent internalization of the human melanocortin-4 receptors in human embryonic kidney 293 cells. J Pharmacol Exp Ther. 2003; 307: 870-7.
30. Shinyama H, Masuzaki H, Fang H, Flier JS. Regulation of melanocortin-4 receptor signaling: agonist-mediated desensitization and internalization. Endocrinology. 2003; 144: 1301-14.
31. Nickolls SA, Fleck B, Hoare SR, Maki RA. Functional selectivity of melanocortin 4 receptor peptide and nonpeptide agonists: evidence for ligand-specific conformational states. J Pharmacol Exp Ther. 2005; 313: 1281-8.
32. Mohammad S, Baldini G, Granell S, Narducci P, Martelli AM, Baldini G. Constitutive traffic of melanocortin-4 receptor in neuro2A cells and immortalized hypothalamic neurons. J Biol Chem. 2007; 282: 4963-74.
33. McDaniel FK, Molden BM, Mohammad S, Baldini G, McPike L, Narducci P, et al. Constitutive cholesterol-dependent endocytosis of melanocortin-4 receptor (MC4R) is essential to maintain receptor responsiveness to α-melanocyte-stimulating hormone (α-MSH). J Biol Chem. 2012; 287: 21873-90.
34. Rus R, Haag C, Bumke-Vogt C, Bahr V, Mayr B, Mohlig M, et al. Novel inactivating mutations of the calcium-sensing receptor: the calcimimetic NPS R-568 improves signal transduction of mutant receptors. J Clin Endocrinol Metab. 2008; 93: 4797-803.
35. Irannejad R, Tomshine JC, Tomshine JR, Chevalier M, Mahoney JP, Steyaert J, et al. Conformational biosensors reveal GPCR signalling from endosomes. Nature. 2013; 495: 534-8.
36. Robben JH, Kortenoeven ML, Sze M, Yae C, Milligan G, Oorschot VM, et al. Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists. Proc Natl Acad Sci U S A. 2009; 106: 12195-200.